|
| |
|
DR. S. B. KATTI |
|
| |
 |
|
Scientist F
Medicinal & Process Chemistry Division
Central Drug Research Institute
Lucknow- 226001 |
|
| Educational Qualifications |
M. Pharm., Ph.D |
| Date of Birth |
28th November, 1953 |
| E Mail |
setu_katti@yahoo.com |
| Phone |
0522-2612411-18 PABX Ext.
4447, 4373 (O)
0522-2620586 (O)
0522- 2788912 (R) |
|
| |
| POST-DOCTORAL
RESEARCH |
| |
| • |
University
of Zurich (1981- 1982) |
| • |
University
of Chicago ( 1982- 1986 ) |
|
| |
| FIELDS
OF SPECIALISATION |
| |
| • |
Medicinal
Chemistry and Bioorganic Chemistry |
|
| |
|
AREAS OF INTEREST |
| |
| • |
Malaria Chemotherapy,
Anti-HIV & Antidiabetic Agents |
|
| |
| PUBLICATIONS
: 70 in peer reviewed journals |
| |
| PATENTS
|
| • |
Indian Patent
|
Seven |
| • |
US patent |
Two |
| • |
EU patent |
Two |
|
| |
| SELECTED
PUBLICATIONS |
| |
• |
Synthesis and evaluation
of 2-(2,6-dihalophenyl)-3-pyrimidinyl-1,3-thiazolidin-4-
one analogues as anti-HIV-1 agents, R. K.Rawal, R. K.Tripathi,
S. B. Katti, C. Pannecouque, Erik De
Clercq, Bioorganic Med. Chem., (2007),
15, 3134-42 |
• |
Design, synthesis, and
evaluation of 2-aryl-3-heteroaryl-1,3- thiazolidin-4-ones
as anti-HIVagentsRavindra K. Rawal,Rajkamal Tripathi,
S. B. Katti, Christophe Pannecouque and Erik De Clercq,
Bioorganic Med. Chem., 2007, 15, 1725-31. |
• |
Synthesis and Antimalarial
Activity of Side Chain Modified 4-Aminoquinoline Derivatives.
V. Raja Solomon, W. Haq, Kumkum Srivastava, Sunil K. Puri,
S. B. Katti, J. Med. Chem., 2007, 50(2),
394-98 |
• |
Synthesis and biological
evaluation 2,3-diaryl substituted 1,3, tiazolidin-4-ones
as anti HIV agents. R. K. Rawal, R. K. Tripathi, S.
B. Katti, C. Pannecouque, E. De Clercq,
Medicinal Chemistry, 2007, 3, 0000 |
• |
2-(2,6-Dichlorophenyl)-3-(quinolin-2-yl)thiazolidin-4-one.
R. Raghunandan, R. K. Rawal, S. B. Katti
and P. R. Maulik. Acta Cryst., 2006,
E62, o5349-o5351. |
• |
Molecular Surface Features
in Modeling the HIV-1 RT Inhibitory Activity of 2-(2,6-Disubstituted
phenyl)-3-(substituted pyrimidin-2-yl)-thiazolidin-4-ones.
R. K. Rawal,Y. S. Prabhakar, S. B. Katti.
QSAR & Combinatorial Science, 2007,
26, 398-406 |
• |
Molecular docking studies
on 4-thiazolidinones as HIV-1RT inhibitors. R. K. Rawal,
A. Kumar, M. I. Siddiqi, S. B. Katti. J Mol Model,
2007, 13, 155-61 |
• |
QSAR and Molecular Modeling
Studies in Heterocyclic Drugs II Series: Topics
in Heterocyclic Chemistry, Vol. 4., 2006,
Gupta, S.P.(Ed.), Chapter Title. QSAR Studies on Thiazolidines:
A Biologically Privileged Scaffold Y.S. Prabhakar, V.
Raja Solomon, M.K. Gupta, S. B. Katti.
(Book Chapter) |
• |
Design, Synthesis and
Antimalarial activity of a new class of Iron chelators
V.Raja Solomon, W.Haq, Sunil K. Puri, Kumkum Srivastava,
S.B.Katti, Medicinal Chemistry,
2006, 2,1-6. |
• |
Tryptophan residue is
essential for immunoreactivity of a diagnostically relevant
peptide epitope of A. fumigatus, Neel Kamal, Shantanu
Chowdhury, Taruna Madan, Deepak Sharma, M. Attreyi, Wahajul
Haq, Seturam Bandacharya Katti, Anil Kumar and P. Usha
Sarma; Molecular and Cellular Biochemistry, 2005,
275, 223–231 |
• |
Design and synthesis of
new antimalarial agents from 4-aminoquinoline, V. Raja
Solomon, Sunil K. Puri, Kumkum Srivastava, S.B.Katti,
Bioorg.Med.Chem. 2005,13, , 2157-2165. |
• |
2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones
as selective HIV-RT Inhibitors, Ravindra K. Rawal,Yenamandra
S. Prabhakar, S. B. Katti and E. De Clercq;
Bioorganic medicinal chemistry, 2005,
13, 6771-6776. |
• |
Synthesis and QSAR studies
on Thiazolidinones as HIV-RT Inhibitors R. K. Rawal, V.
Raja Solomon, Y. S. Prabhakar, S. B. Katti
and E. De Clercq; Combinatorial Chemistry and
High-throughput screening, 2005, 8, 439-443. |
• |
Topological descriptors
in modeling the HIV-RT inhibitory activityof 2-aryl-3-pyridyl-thiazolidin-4-one,Y.
S. Prabhakar, R. K. Rawal, M. K. Gupta, V. Raja Solomon
and S. B. Katti, Combinatorial
Chemistry and High-throughput screening, 2005,
8, 431-437. |
| |
| |
|
|
| |
|
| |
|